Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Alan Schoenfeld, Ph.D.

Co-Author

This page shows the publications co-authored by David Schoenfeld and A. Evins.
Connection Strength

2.520
  1. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014 Jan 08; 311(2):145-54.
    View in: PubMed
    Score: 0.628
  2. Schuster RM, Potter K, Vandrey R, Hareli M, Gilman J, Schoenfeld D, Evins AE. Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. J Psychopharmacol. 2020 02; 34(2):197-210.
    View in: PubMed
    Score: 0.233
  3. Schuster RM, Hareli M, Moser AD, Lowman K, Gilman J, Ulysse C, Schoenfeld D, Evins AE. Cross-domain correlates of cannabis use disorder severity among young adults. Addict Behav. 2019 06; 93:212-218.
    View in: PubMed
    Score: 0.223
  4. Schuster RM, Gilman J, Schoenfeld D, Evenden J, Hareli M, Ulysse C, Nip E, Hanly A, Zhang H, Evins AE. One Month of Cannabis Abstinence in Adolescents and Young Adults Is Associated With Improved Memory. J Clin Psychiatry. 2018 10 30; 79(6).
    View in: PubMed
    Score: 0.219
  5. Schuster RM, Cather C, Pachas GN, Zhang H, Cieslak KM, Hoeppner SS, Schoenfeld D, Evins AE. Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. Addict Behav. 2017 08; 71:89-95.
    View in: PubMed
    Score: 0.195
  6. Evins AE, Hoeppner SS, Schoenfeld DA, Hoeppner BB, Cather C, Pachas GN, Cieslak KM, Maravic MC. Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. Schizophr Res. 2017 05; 183:124-129.
    View in: PubMed
    Score: 0.192
  7. Wang R, Schoenfeld DA, Hoeppner B, Evins AE. Detecting treatment-covariate interactions using permutation methods. Stat Med. 2015 May 30; 34(12):2035-47.
    View in: PubMed
    Score: 0.170
  8. Roh S, Hoeppner SS, Schoenfeld D, Fullerton CA, Stoeckel LE, Evins AE. Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology (Berl). 2014 Feb; 231(4):765-75.
    View in: PubMed
    Score: 0.154
  9. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007 Aug; 27(4):380-6.
    View in: PubMed
    Score: 0.101
  10. Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry. 2005 Sep; 66(9):1184-90.
    View in: PubMed
    Score: 0.088
  11. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):218-25.
    View in: PubMed
    Score: 0.087
  12. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr; 179(1):144-50.
    View in: PubMed
    Score: 0.083
  13. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003 May-Jun; 72(3):115-27.
    View in: PubMed
    Score: 0.075
  14. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008 Dec; 106(2-3):320-7.
    View in: PubMed
    Score: 0.027
  15. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006 May; 67(5):789-97.
    View in: PubMed
    Score: 0.023
  16. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins AE, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005 01; 62(1):19-28.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.